Compare CRCT & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRCT | TYRA |
|---|---|---|
| Founded | 1969 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2021 | 2021 |
| Metric | CRCT | TYRA |
|---|---|---|
| Price | $4.95 | $26.05 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $4.18 | ★ $32.17 |
| AVG Volume (30 Days) | 452.9K | ★ 546.0K |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | ★ 19.39% | N/A |
| EPS Growth | ★ 27.98 | N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $714,492,000.00 | N/A |
| Revenue This Year | $1.06 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.26 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.94 | $6.42 |
| 52 Week High | $7.33 | $26.09 |
| Indicator | CRCT | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 44.63 | 76.73 |
| Support Level | $4.94 | $24.65 |
| Resistance Level | $5.35 | $26.09 |
| Average True Range (ATR) | 0.14 | 1.37 |
| MACD | -0.01 | 0.15 |
| Stochastic Oscillator | 8.79 | 93.84 |
Cricut Inc designs and builds a creativity platform that enables users to turn ideas into professional-looking handmade goods. With its connected machines, design apps and accessories, and materials, the users create everything from personalized birthday cards, mugs and T-shirts to large-scale interior decorations. It has two segments including the Platform segment which derives revenue from monthly and annual subscription fees, purchases of digital content, and a minimal amount of the revenue allocated to unspecified future upgrades and enhancements related to the essential software and access to the Company's cloud-based services and Products segment which derives revenue from the sale of its connected machine hardware, and sale of craft, DIY, home decor products and extensions.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.